Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine

Wijemanne, Subhashie; Jankovic, Joseph; Evans, Randolph W.

doi:10.1111/head.12712

Cited by 29 publications

(19 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since TD may also be used to describe multiple drug-induced extrapyramidal disorders including CTD, tardive akathisia, tardive dystonia, tardive tremor, etc. ( Wijemanne et al, 2016 , Waln and Jankovic, 2013 ), it is necessary to evaluate these related adverse events in our FAERS queries to account for generalized or inaccurate reporting. The UOR scores related to the overall movement-related adverse events (MedDRA terms: extrapyramidal disorder, movement disorder, dyskinesia, akathisia, dystonia, and tremor) are shown in Table S3 and Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Metoclopramide (MCP) is an antiemetic and gastrointestinal (GI) agent, and the only medication approved by the U.S. Food and Drug Administration (FDA) for the indication of gastroparesis. The mechanism of action is its dopamine (DA) receptor antagonistic activity which suppresses the effects of DA and promotes the release of acetylcholine (Ach) ( Wijemanne et al, 2016 ). The increase of Ach level improves the symptoms of gastroparesis by speeding up stomach muscle movement and stomach emptying.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

Xu¹,

Ham²,

Tivis³

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

In 2009 the U.S. Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD). In this study, we developed a multi-step biomedical informatics screening (MSBIS) approach leveraging publicly available bioactivity and drug safety data to identify concomitant drugs that mitigate the risks of MCP-induced TD. MSBIS includes (1) TargetSearch (http://dxulab.org/software) bioinformatics scoring for drug anticholinergic activity using CHEMBL bioactivity data; (2) unadjusted odds ratio (UOR) scoring for indications of TD-mitigating effects using the FDA Adverse Event Reporting System (FAERS); (3) adjusted odds ratio (AOR) re-scoring by removing the effect of cofounding factors (age, gender, reporting year); (4) logistic regression (LR) coefficient scoring for confirming the best TD-mitigating drug candidates. Drugs with increasing TD protective potential and statistical significance were obtained at each screening step. Fentanyl is identified as the most promising drug against MCP-induced TD (coefficient: −2.68; p-value < 0.01). The discovery is supported by clinical reports that patients fully recovered from MCP-induced TD after fentanyl-induced general anesthesia. Loperamide is identified as a potent mitigating drug against a broader range of drug-induced movement disorders through pharmacokinetic modifications. Using drug-induced TD as an example, we demonstrated that MSBIS is an efficient in silico tool for unknown drug-drug interaction detection, drug repurposing, and combination therapy design.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

Xu¹,

Ham²,

Tivis³

et al. 2017

EBioMedicine

View full text Add to dashboard Cite

show abstract

“…Entre estos medicamentos, se encuentran antipsicóticos, antidepresivos tricíclicos y antieméticos intestinales (metoclopramida), entre otros. Tiene diferentes presentaciones clínicas, donde se incluye la acatisia tardía, corea tardía, tic/Tourette tardío, mioclonía tardía y también distonía tardía, las cuales pueden afectar a segmentos de tronco, con inclinación lateral (síndrome de Pisa) y alteraciones de la marcha por posturas anómalas (35)(36)(37)(38)(39)(40)(41)(42).…”

Section: Discinesia Tardíaunclassified

Extrapiramidalismo por antieméticos

Mogollón

Díaz

2020

Rev. Med.

View full text Add to dashboard Cite

Los antieméticos son usados frecuentemente por diversas áreas de la medicina, aunque existe una tendencia a subestimar sus efectos adversos neurológicos. El objetivo del presente estudio de revisión fue revisar la literatura sobre la fisiología, farmacología, factores predisponentes, clínica y manejo del extrapiramidalismo por antieméticos. Se realizó una búsqueda en la literatura de artículos de revistas científicas, libros y trabajos de grado. Se utilizaron los buscadores Medline, lilacs, PubMed, embase, Current contents y Google Scholar con las siguientes palabras claves: deshidratación, gastroenteritis, vómitos, antieméticos, distonía, dopamina, hipertermia, citocromo, metoclopramida y domperidona. Se obtuvieron 252 artículos, de los cuales 50 fueron considerados aptos para la revisión. A partir del análisis, se concluyó que el uso de antieméticos es de uso frecuente por medicina general y especialidades como anestesiología y pediatría, por lo cual un conocimiento sobre los efectos extrapiramidales permitirá un diagnóstico y manejo temprano.

show abstract

“…Tardive dyskinesia, an irreversible involuntary motor disorder, has never been reported after an isolated dose of an antidopaminergic. 27 The triptans are serotonin receptor agonists that, during the last 30 years, have revolutionized the outpatient treatment of migraine. 28 Although originally developed as vasoconstrictors, these medications decrease nociceptive transmission within the trigeminal pathway.…”

Section: Treatmentmentioning

confidence: 99%

Managing Migraine

Friedman

2017

Annals of Emergency Medicine

View full text Add to dashboard Cite

Editor's Note: The Expert Clinical Management series consists of shorter, practical review articles focused on the optimal approach to a specific sign, symptom, disease, procedure, technology, or other emergency department challenge. These articles-typically solicited from recognized experts in the subject area-will summarize the best available evidence relating to the topic while including practical recommendations where the evidence is incomplete or conflicting.

show abstract

Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine

Cited by 29 publications

References 68 publications

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

Extrapiramidalismo por antieméticos

Managing Migraine

Contact Info

Product

Resources

About